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ABSTRACT [1]
GPR17 is a class A-GPCRs operated by dierent classes of ligands, such as uracil nucleotides, cysteinyl-leukotrienes and oxysterols. Similar to other receptors of the same class, GPR17 can associate into homo- and 
hetero-dimers. Recent ndings suggest its promiscuous behaviour namely the possibility to be operated by ligands able to transversely interact with more than one GPCRs. In fact, both GPR17 and CXCR2 are operated 
by oxysterols, and both GPR17 and CXCRn ligands have demonstrated roles in orchestrating inammatory responses and oligodendrocyte precursor cell (OPC) dierentiation to myelinating cells in acute and chronic 
diseases of the CNS. Here we demonstrate that GPR17 can be activated by the chemokine stromal-derived factor-1 (SDF-1), a ligand of  CXCR4 and CXCR7, and investigate the underlying molecular recognition           
mechanism, by combining in silico modelling data with in vitro validation in (i) a classical reference pharmacological assay for GPCR activity and (ii) a model of maturation of primary OPCs. We also demonstrate that 
cangrelor, a GPR17 orthosteric antagonist, can block the SDF-1-mediated activation of GPR17 in a concentration-dependent manner. The ability of GPR17 to respond to dierent classes of GPCR ligands suggests that 
this receptor modies its function depending on changes occurring in the extracellular mileu changes occurring under specic pathophysiological conditions and advocates it as a strategic target for                                 
neurodegenerative diseases with an inammatory/immune component.  
MODELING AND MOLECULAR DYNAMICS SIMULATION
GPR17::SDF-1 artwork, powered by 
Studio Bozzetto.
Stability of GPR17::SDF-1 during MD simulation.
Total energy and interaction energy (light grey) are plotted vs time in 
panels (A) and (B), respectively. Panel (C) shows the RMSD proles vs 
time for SDF-1 (grey) and GPR17 (black), whereas panel (D) shows the 
RMS uctuation, expressed in nm, computed for the α-carbons of SDF-1 
(light grey, residues 1–68) and GPR17 (dark grey, residues 1–304). Panel 
(E) reports as a function of time the total number of contacts between 
all pairs of residues, panel (F) the total number of hydrogen bonds oc-
curring between SDF-1 and GPR17 (in black); panel (F) also shows the 
number of atom pairs < 0.35 nm apart (in grey).
Comparative model of the GPR17::SDF-1 complex. 
Regions built using P2Y12 as template are represented as green 
ribbons; residues transferred from other templates are                         
highlighted in yellow (IL3, from rhodopsin) and orange                   
(N-terminus, from the CXCR4::SDF-1 in Tamamis at al. [2]). 
SDF-1 (from the CXCR4::SDF-1 in Tamamis at al. [2]) is in grey.    
INTERACTION BETWEEN GPR17 AND SDF-1
SDF-1-MEDIATED GPR17 ACTIVATION
SDF-1-mediated activation of GPR17 in OPCs. 
MBP-expressing cells (in red) treated with vehicle (A) and 
SDF-1 alone (B), or in combination with cangrelor (C) and    
plerixafor, an CXCR4 antagonist (D). (E) Control cell cultures 
expressing GPR17 (in green) and MBP (in red). Cell nuclei are 
labelled with Hoechst 33258 (in blue). (F) Percentage of MBP+ 
cells after  treatment with vehicle and with SDF-1 alone, or in 
combination with cangrelor  and plerixafor.
In order to investigate the molecular behaviour of the 
GPR17::SDF-1 complex, we carried out a 43 ns MD        
simulation with CHARMM using a Generalized Born 
method with a simple switching (GBSW) model of          
implicit membrane/solvent. The evaluation of the     
stability of the GPR17::SDF-1 complex during the      
production phase was based both on energetic and 
geometric parameters. The general stability of the 
GPR17::SDF-1 complex is conrmed by the tendency 
of the MD simulations to reach convergence after 20 
ns.
•
•
•
TM binding pocket of GPR17. 
Representative picture of the residue Lys1 (labelled sticks), at the extremity of SDF-1 N-
terminus (white ribbons) entering the TM binding pocket of GPR17 (green ribbons).
TM are also involved:
Lys1 of SDF-1, essential for the chemotactic activity toward 
CXCR4, exhibits specic H-bond interactions with the –OH 
groups of Tyr112 (TM3), Tyr251 (TM6), and Tyr262 (EL3), and with 
polar groups of residues Asn279 (TM7) and Gln183 (EL2). While 
our previous studies on GPR17 reported that all these residues 
are likely involved in the recognition of uracil nucleotides, in 
SDF-1 neither His255 nor Arg255 are directly involved in the       
recognition mechanism. 
During the whole MD simulation we found 
eighty-six pairs of residues involved in the  
GPR17::SDF-1 interaction.
Twenty-one pairs of these residues form            
interactions conserved in the CXCR4::SDF-1        
complex [2]. 
Among the conserved interactions, ten are 
stable throughout the MD simulation: Lys1-
Tyr112; Lys1–Tyr251; Lys1–Asn279; Ser–Gln25; 
Asn33–Asn2; Gln48–Ala18; Gln48–Ala18; 
Gln48–Thr19; Gln48–Ala20; Glu21–Lys27.
Our in silico data suggest that the binding      
surface of SDF-1 on GPR17 is diused and that 
both the N-terminus and the ELs are important 
for molecular recognition, as already described 
for many peptide ligands of GPCRs. 
Uracil nucleotide binding site of GPR17.
Superposition between SDF-1 (light grey molecular surface and ribbons) and cangrelor (sticks,          
atom-type colour code) in the TM, orthosteric, binding site of GPR17 (grey ribbons).
GPR17::SDF-1 interaction spatial map.
Intermolecular interactions between pairs of residues in 
GPR17::SDF-1 are represented by lines; multiple interactions 
are represented with light green lines.
The nucleotide-derivative antagonist cangrelor [4] binds the same TM binding 
pocket, establishing specic interactions with some residues involved in the 
SDF-1 recognition; this features suggest that cangrelor may hamper the            
entrance of SDF-1 N-terminus in the TM binding site.
•
•
•
•
•
•
Besides activating its cognate receptors CXCR4 and CXCR7, SDF-1 can also activate GPR17 with             
comparable potency, as predicted by our in silico simulation. In our in vitro models, the activation of 
GPR17 by SDF-1 eciently promotes the maturation of OPCs, a well-known key event of the                   
myelination pathway. This emphasizes the pathophysiological relevance of the cross-talk between 
these receptors in the regulation of OPC maturation and myelination.
Research activity was sponsored by Fondazione Italiana Sclerosi Multipla (FISM) to LP (2014/B/5), to MPA (2013/R/1) 
and to IE and MPA (2013/S/2). CP was supported by a Fondazione Umberto Veronesi Fellowship. Special thanks to 
Prof. Francesca Fanelli, Università degli Studi di Modena e Reggio Emilia, for supporting us in the setup of MD            
simulation, and to Drs. Elisabetta Bonfanti and Davide Lecca, Università degli Studi di Milano, for their helpful           
discussion. Special thanks to Studio Bozzetto for the artwork  of GPR17::SDF-1.
AcknowledgementsReferences
[1] C. Parravicini et al., A promiscuous recognition mechanism between GPR17 and SDF-1: Molecular insights. Cell. Signal., 2016, 28, 631–642 
[2] P. Tamamis et al., Elucidating a key component of cancer metastasis: CXCL12 (SDF-1alpha) binding to CXCR4. J. Chem. Inf. Model., 2014, 28,1174–1188
[3] C. Parravicini et al., GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y re-
ceptors. BMC Bioinf., 2008, 9, 263
[4] I. Eberini et al., In silico identication of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J. Comput. Aided Mol. Des., 
2011, 25, 743–752
FISM grant 2014
    
We modeled the GPR17::SDF-1 complex using 
functional and structural information on SDF1 
and on CXCR4 as partial homologous template for 
GPR17:
Crystal structures are available for both CXCR4 
and SDF-1.
Functional evidence suggests interaction 
between SDF1 and CXCR4.
A model of CXCR4::SDF-1 has been published          
by Tamamis et al. [2].
P2Y12 and Rho are the most appropriate partial 
homologous templates for the TM bundle of 
GPR17.
CONCLUSIONS In primary OPC cultures, treatment with SDF-1 increases 
the number of MBP+ cells with respect to control. This        
increase is not observed when SDF-1 is added to cells 
either in combination with cangrelor or plerixafor. In both 
antagonist groups, the number of MBP+ cells is                  
comparable to, or slightly lower than, the one measured in 
the vehicle-treated cells. 
[35S]GTPγS binding experiments performed on 1321N1 cells stably transfected 
with GPR17 demonstrate that SDF-1 is able to increase the GTPγS binding to cell 
membranes, with anity constant values of 0.14 ± 0.03 nM. This eect is            
completely antagonized by the well-known GPR17 orthosteric antagonist         
cangrelor, further conrming that SDF-1 specically bound GPR17 and behaved 
as a receptor agonist.
Pharmacological prole of SDF-1 to GPR17: [35S]GTPγS binding. 
((A) Membrane aliquots obtained from 1321N1 cells transfected with hGPR17 were incubated with               
dierent SDF-1 concentrations, and [35S]GTPγS binding assay was performed. (B) Eect of the GPR17          
receptor antagonist cangrelor on ligand-stimulated [35S]GTPγS binding. Membranes from human 
GPR17-transfected cells were pre-incubated for 10 min with cangrelor (0.1 nM–100 nM), then stimulated 
with SDF-1 at the constant concentration of 1.5 nM (10 fold over the EC50 value). 
